{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T15:05:56Z","timestamp":1784991956839,"version":"3.55.0"},"reference-count":29,"publisher":"Japanese Circulation Society","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Circ J"],"published-print":{"date-parts":[[2025,4,25]]},"DOI":"10.1253\/circj.cj-25-0086","type":"journal-article","created":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T22:06:13Z","timestamp":1743113173000},"page":"638-646","source":"Crossref","is-referenced-by-count":3,"title":["Impact of Guideline-Directed Medical Therapy on 2-Year Mortality in Japanese Patients Undergoing Endovascular Therapy for Femoropopliteal Lesions\u3000\u2015 Results of the Multicenter GEMINI-FP Study \u2015"],"prefix":"10.1253","volume":"89","author":[{"given":"Tatsuro","family":"Takei","sequence":"first","affiliation":[{"name":"Department of Cardiology, Tenyoukai Central Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Tokuda","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Nagoya Heart Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Yoshioka","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Ogaki Municipal Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Ogata","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Miyazaki Medical Association Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Sendai Kousei Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Kojima","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Tokyo Bay Urayasu Ichikawa Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Yamaguchi","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Saiseikai Yokohama City Eastern Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Yanagiuchi","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Rakuwakai Otowa Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Nakama","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Tokyo Bay Urayasu Ichikawa Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the LEADers PAD Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"330","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Criqui MH, Matsushita K, Aboyans V, Hess CN, Hicks CW, Kwan TW, et al. Lower extremity peripheral artery disease: Contemporary epidemiology, management gaps, and future directions: A scientific statement from the American Heart Association. <i>Circulation<\/i> 2021; 144: e171\u2013e191.","DOI":"10.1161\/CIR.0000000000001005"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Gerhard-Herman MD, Gornik HL, Barrett C, Barshes NR, Corriere MA, Drachman DE, et al. 2016 AHA\/ACC guideline on the management of patients with lower extremity peripheral artery disease: A report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. <i>Circulation<\/i> 2017; 135: e726\u2013e779.","DOI":"10.1161\/CIR.0000000000000502"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Heart Outcomes Prevention Evaluation Study Investigators; Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. <i>N Engl J Med<\/i> 2000; 342: 145\u2013153.","DOI":"10.1056\/NEJM200001203420301"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. B\u00fcchner N, Banas B, Kr\u00e4mer BK. Telmisartan, ramipril, or both in patients at high risk of vascular events. <i>N Engl J Med<\/i> 2008; 359: 426.","DOI":"10.1056\/NEJMc081065"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Armstrong EJ, Chen DC, Westin GG, Singh S, McCoach CE, Bang H, et al. Adherence to guideline-recommended therapy is associated with decreased major adverse cardiovascular events and major adverse limb events among patients with peripheral arterial disease. <i>J Am Heart Assoc<\/i> 2014; 3: e000697.","DOI":"10.1161\/JAHA.113.000697"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Smolderen KG, Romain G, Provance JB, Scierka LE, Mao J, Goodney PP, et al. Guideline-directed medical therapy and long-term mortality and amputation outcomes in patients undergoing peripheral vascular interventions. <i>JACC Cardiovasc Interv<\/i> 2023; 16: 332\u2013343.","DOI":"10.1016\/j.jcin.2022.09.022"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Bhatt DL, Eagle KA, Ohman EM, Hirsch AT, Goto S, Mahoney EM, et al. Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. <i>JAMA<\/i> 2010; 304: 1350\u20131357.","DOI":"10.1001\/jama.2010.1322"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Hata Y, Iida O, Okamoto S, Ishihara T, Nanto K, Tsujimura T, et al. Impact of guideline-directed medical therapy on 10-year mortality after revascularizatio n for patients with chronic limb-threatening ischemia. <i>J Atheroscler Thromb<\/i> 2023; 30: 663\u2013674.","DOI":"10.5551\/jat.63773"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Lee JH, Jeon HS, Lee JW, Youn YJ, Ahn SG, Kim H, et al. Impact of guideline-directed medical therapy on 5-year mortality in patients with newly diagnosed peripheral artery disease. <i>J Vasc Surg<\/i> 2023; 78: 1471\u20131478.e3.","DOI":"10.1016\/j.jvs.2023.08.103"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Antithrombotic Trialists\u2019 Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. <i>BMJ<\/i> 2002; 324: 71\u201386.","DOI":"10.1136\/bmj.324.7329.71"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Heart Protection Study Collaborative Group. Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions. <i>J Vasc Surg<\/i> 2007; 45: 645\u2013654.","DOI":"10.1016\/j.jvs.2006.12.054"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Antoniou GA, Fisher RK, Georgiadis GS, Antoniou SA, Torella F. Statin therapy in lower limb peripheral arterial disease: Systematic review and meta-analysis. <i>Vascul Pharmacol<\/i> 2014; 63: 79\u201387.","DOI":"10.1016\/j.vph.2014.09.001"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Ramos R, Garc\u00eda-Gil M, Comas-Cuf\u00ed M, Quesada M, Marrugat J, Elosua R, et al. Statins for prevention of cardiovascular events in a low-risk population with low ankle brachial index. <i>J Am Coll Cardiol<\/i> 2016; 67: 630\u2013640.","DOI":"10.1016\/j.jacc.2015.11.052"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Watanabe H, Morimoto T, Yamamoto K, Obayashi Y, Natsuaki M, Yamaji K, et al. Prevalence and effects of high-intensity statins for Japanese patients presenting with acute coronary syndrome: A post hoc secondary analysis of STOPDAPT-2 ACS. <i>Circ J<\/i> 2023; 87: 657\u2013668.","DOI":"10.1253\/circj.CJ-22-0650"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Armstrong EJ, Chen DC, Singh GD, Amsterdam EA, Laird JR. Angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use is associated with reduced major adverse cardiovascular events among patients with critical limb ischemia. <i>Vasc Med<\/i> 2015; 20: 237\u2013244.","DOI":"10.1177\/1358863X15574321"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Khan SZ, O\u2019Brien-Irr MS, Rivero M, Blochle R, Cherr GS, Dryjski ML, et al. Improved survival with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in chronic limb-threatening ischemia. <i>J Vasc Surg<\/i> 2020; 72: 2130\u20132138.","DOI":"10.1016\/j.jvs.2020.02.041"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Saito Y, Kobayashi Y, Tsujita K, Kuwahara K, Ikari Y, Tsutsui H, et al. Pharmacological and device-based intervention for preventing heart failure after acute myocardial infarction: A clinical review. <i>Circ J<\/i> 2024; 88: 1727\u20131736.","DOI":"10.1253\/circj.CJ-24-0633"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Herrington W, Lacey B, Sherliker P, Armitage J, Lewington S. Epidemiology of atherosclerosis and the potential to reduce the global burden of atherothrombotic disease. <i>Circ Res<\/i> 2016; 118: 535\u2013546.","DOI":"10.1161\/CIRCRESAHA.115.307611"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Kwan TW, Wong SS, Hong Y, Kanaya AM, Khan SS, Hayman LL, et al. Epidemiology of diabetes and atherosclerotic cardiovascular disease among Asian American adults: Implications, management, and future directions: A scientific statement from the American Heart Association. <i>Circulation<\/i> 2023; 148: 74\u201394.","DOI":"10.1161\/CIR.0000000000001145"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Takahara M, Soga Y, Iida O. Lower extremity arterial disease vs. coronary artery disease: Mortality differences after revascularization. <i>Eur Heart J<\/i> 2024; 45: 1634\u20131643.","DOI":"10.1093\/eurheartj\/ehae207"},{"key":"21","doi-asserted-by":"publisher","unstructured":"21. Minnick C, Stafford J, Stutsrim A, Williams TK, Chang K, Sanin G, et al. Prescriber implementation of guideline-directed medical therapy remains poor in the peripheral artery disease population. <i>J Vasc Surg<\/i> 2025, doi:10.1016\/j.jvs.2025.02.011.","DOI":"10.1016\/j.jvs.2025.02.011"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Jelani QU, Llanos-Chea F, Bogra P, Trejo-Paredes C, Huang J, Provance JB, et al. Guideline-directed medical therapy in patients with chronic kidney disease undergoing peripheral vascular intervention. <i>Am J Nephrol<\/i> 2021; 52: 845\u2013853.","DOI":"10.1159\/000519484"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Nishihira K, Nakai M, Kuriyama N, Kadooka K, Honda Y, Emori H, et al. Guideline-directed medical therapy for elderly patients with acute myocardial infarction who undergo percutaneous coronary intervention: Insights from a retrospective observational study. <i>Circ J<\/i> 2024; 88: 931\u2013937.","DOI":"10.1253\/circj.CJ-23-0837"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Matsukawa R, Kabu K, Koga E, Hara A, Kisanuki H, Sada M, et al. Optimizing guideline-directed medical therapy during hospitalization improves prognosis in patients with worsening heart failure requiring readmissions. <i>Circ J<\/i> 2024; 88: 1416\u20131424.","DOI":"10.1253\/circj.CJ-24-0265"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. White C. Clinical practice. Intermittent claudication. <i>N Engl J Med<\/i> 2007; 356: 1241\u20131250.","DOI":"10.1056\/NEJMcp064483"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Iida O, Fujihara M, Kawasaki D, Mori S, Yokoi H, Miyamoto A, et al. 24-Month efficacy and safety results from Japanese patients in the IMPERIAL randomized study of the Eluvia drug-eluting stent and the Zilver PTX drug-coated stent. <i>Cardiovasc Intervent Radiol<\/i> 2021; 44: 1367\u20131374.","DOI":"10.1007\/s00270-021-02901-6"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Lammer J, Zeller T, Hausegger KA, Schaefer PJ, Gschwendtner M, Mueller-Huelsbeck S, et al. Heparin-bonded covered stents versus bare-metal stents for complex femoropopliteal artery lesions: The randomized VIASTAR trial (Viabahn endoprosthesis with PROPATEN bioactive surface [VIA] versus bare nitinol stent in the treatment of long lesions in superficial femoral artery occlusive disease). <i>J Am Coll Cardiol<\/i> 2013; 62: 1320\u20131327.","DOI":"10.1186\/ISRCTN48164244"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Ogata K, Nishihira K, Asano Y, Honda Y, Yamamoto K, Emori H, et al. Clinical comparison of drug-coated balloon and drug-eluting stent for femoropopliteal lesions in chronic limb-threatening ischemia with wounds. <i>Circ J<\/i> 2024; 88: 1647\u20131655.","DOI":"10.1253\/circj.CJ-24-0176"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Guntani A. Revascularization of the femoropopliteal artery region. <i>Ann Vasc Dis<\/i> 2024; 17: 219\u2013221.","DOI":"10.3400\/avd.ra.24-00065"}],"container-title":["Circulation Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/89\/5\/89_CJ-25-0086\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T03:14:50Z","timestamp":1745637290000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/89\/5\/89_CJ-25-0086\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,25]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1253\/circj.cj-25-0086","relation":{},"ISSN":["1346-9843","1347-4820"],"issn-type":[{"value":"1346-9843","type":"print"},{"value":"1347-4820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,25]]},"article-number":"CJ-25-0086"}}